On August 9, 2023, ImmunoPrecise Antibodies Ltd announced that it has issued a statement in response to the filing made on July 7, 2023, by Ingalls & Snyder LLC, stating that the Company?s Board of Directors and management team value constructive input and welcome open communication with shareholders including Ingalls & Snyder, committed to acting in the best interest of the Company and strive to have the optimal board of directors? composition to attain Company?s strategic priorities and to maximize long-term shareholder value, and had opened the dialogue with Ingalls & Snyder LLC and will continue to engage in discussions with them as we carefully consider their views.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | +10.55% | +4.76% | -22.81% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.81% | 34.74M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- IPA Stock
- News ImmunoPrecise Antibodies Ltd.
- ImmunoPrecise Antibodies Ltd Issues a Response to Ingalls & Snyder LLC Filing